Gynecologic Cancers

Prexasertib is currently under investigation as part of a phase 2 trial as a treatment for patients with platinum-resistant ovarian cancer, endometrial adenocarcinoma, and urothelial cancers.

A recovery tracker and other digital tools may be useful in helping to manage patient symptoms following debulking surgery for gynecologic cancer, according to an expert from Memorial Sloan Kettering Cancer Center.

Common symptoms following debulking surgery for gynecologic cancer appear to include pain, diarrhea, and nausea, according to an expert from Memorial Sloan Kettering Cancer Center.

Based on findings from the phase 3 MIRASOL trial, investigators plan to submit a supplemental biologics license application for mirvetuximab soravtansine in folate receptor α–positive platinum-resistant ovarian cancer.

“Even in well-resourced countries, there are disparities in exposure to treatments; some of these are rooted deeply in social determinants of health and represent a very complex problem of providing equal access.”

Patients who use a recovery tracker tool appear to experience lower hospital readmission rates following gynecologic cancer debulking surgery compared with those who did not.

Medical oncologists and gynecologic oncologists alike have a shared responsibility to help treat symptoms of neuropathy in patients undergoing chemotherapy for gynecologic cancer, according to an expert from Duke University Medical Center.

Future research assessing cryocompression for those with gynecologic cancers will make use of different products to make the intervention easier and more accessible for patients.

Cryocompression demonstrates potential for preventing chemotherapy-induced neuropathy for those with gynecologic cancers, according to an expert from Duke University Medical Center.

Investigators report that most patients with gynecologic cancers were able to tolerate cryocompression to help manage chemotherapy-induced neuropathy, according to an expert from Duke University Medical Center.

Durvalumab plus tremelimumab and hypofractionated radiotherapy yields observable clinical benefits in patients with gynecologic cancers, according to an expert from The University of Texas MD Anderson Cancer Center.

Findings from a recent 30-year analysis of more than 1,000 gynecologic cancer trials strongly suggest that reporting race and ethnicity must be a required part of clinical research to improve diversity, according to a group of researchers.

Following the results of the phase 3 CALLA trial, Jyoti S. Mayadev, MD, discusses the importance of global clinical multidisciplinary efforts in the locally advanced cervical cancer space.

The randomized, placebo-controlled, double-blind phase 3 CALLA trial assessed the combination of durvalumab and chemoradiotherapy vs placebo and chemoradiotherapy.

Findings from the phase 3 CALLA trial indicated that intensity modulated radiation therapy was administered in 88.1% of patients with high-risk locally advanced cervical cancer treated with durvalumab and chemoradiotherapy vs 88.1% with placebo and chemoradiotherapy.

Results from the ongoing phase 2 IMMUNOCERV trial showed that treatment with the investigational drug PDS0101 — a vaccine — combined with chemotherapy and radiation induced a 100% clinical response in a small group of patients with stage IB3 to IVA cervical cancer.

The FDA has granted mirvetuximab soravtansine-gynx an accelerated approval for the treatment of patients with folate receptor-α-positive platinum-resistant ovarian cancer based on results from the phase 3 SORAYA study.

Jyoti S. Mayadev, MD, indicated that durvalumab (Imfinzi) plus chemotherapy resulted in low rates of high-grade late-onset toxicities in the phase 3 CALLA trial, which may be due in part to the quality of the technology employed during the study.

Jyoti S. Mayadev, MD, indicated that future research for cervical cancer will be focused on combination immune checkpoint inhibitors and biomarker research.

Durvalumab appeared to have no impact on the ability to deliver safe and timely radiation therapy to patients with high-risk locally advanced cervical cancer, according to Jyoti S. Mayadev, MD.

The 12-month progression-free survival rates among patients with high-risk locally advanced cervical cancer were comparable with durvalumab plus chemoradiotherapy vs placebo plus radiotherapy.

Data from the phase 3 CALLA trial indicated that multidisciplinary collaboration and a good quality control strategy are key to providing optimal chemoradiotherapy delivery in locally advanced cervical cancer.

Results from the UK phase 2 PEACOCC trial found improved outcomes with pembrolizumab monotherapy in patients with previously-treated advanced clear cell gynecological cancers.

Ritu Salani, MD, highlights key data from the 2022 ESMO Congress, including those surrounding PARP inhibitor maintenance in advanced ovarian cancer and the latest developments in immunotherapeutics for endometrial and cervical cancer.

Lillian Gien, MD, spoke about continued use of immunotherapy in patients with recurrent clear cell carcinoma of the ovary following results of a trial examining pembrolizumab plus epacadostat.

At 2022 IGCS, Lilian Gien, MD, spoke about a phase 2 trial which analyzed pembrolizumab plus epacadostat in patients with recurrent clear cell carcinoma of the ovary.

Tiffany Sia, MD, spoke about major takeaways from her study and how to implement procedural interventions for patients with gynecologic malignancies who have oligoprogression.

A recent study presented at IGCS 2022 looking at clinical trial enrollment found that Black patients experienced the biggest increase in accrual following an NCI call-to-action for more diversity in clinical trials.

At 2022 IGCS, Tiffany Sia, MD, spoke about using procedural interventions to treat patients with gynecologic malignancies who have oligoprogression on treatment with immune checkpoint inhibitors.

The 24-month follow-up of the phase 1/2 CheckMate 358 trial found nivolumab with or without ipilimumab yielded clinically meaningful, long-lasting responses in patients with recurrent or metastatic cervical cancer.